Arrhythmias & electrophysiology
Statin therapy reduces dementia risk in atrial fibrillation patients receiving oral anticoagulants
Main finding · Dementia (CHA2DS2-VASc ≥2)Result — go to the resultHazard ratio 0.77 95% CI 0.64–0.90Authors' conclusion
In NVAF patients who received OAC, statin therapy lowered the dementia risk compared with no statin therapy. Furthermore, statin therapy is associated with a dose-dependent reduction in dementia risk.
Study context
- Population
- Non-valvular AF (NVAF) patients receiving oral anticoagulant (OAC) (VKA or direct-acting OAC), Korean National Health Insurance Service database, 2013–2017
- Participants
- 91,018 patients
- Exposure
- Statin therapy vs no statin therapy
- Statin therapyn = 17,700
- Non-statin therapyn = 73,318reference
- Outcome
- Occurrence of dementia
- Follow-up
- Median 2.1 years
Methodological detailsnationwide health insurance database
- Nationwide health insurance database
Main finding
Dementia (CHA2DS2-VASc ≥2)
Hazard ratio
0.77
95% CI 0.64–0.90
P = 0.026
Statin therapyvs Non-statin therapy
HR 0.77 (95% CI 0.64–0.90); P = 0.026
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Dose-dependent lower dementia risk with statin vs non-statin therapy
- P for trend < 0.001
Original publication
Statin therapy reduces dementia risk in atrial fibrillation patients receiving oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. Published 8 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →